Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells

References

• Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073 - 8; http://dx.doi.org/10.1038/nbt0905-1073; PMID: 16151394
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278 - 87; http://dx.doi.org/10.1038/nrc3236; PMID: 22437872
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592 - 603; http://dx.doi.org/10.1038/nrc2442; PMID: 18650835
   PubMed Web of Science ®Google Scholar
• Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009; 15:7479 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-09-0636; PMID: 20008848
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443 - 6; http://dx.doi.org/10.1038/74704; PMID: 10742152
   PubMed Web of Science ®Google Scholar
• Glennie MJ, van de Winkel JGJ. Renaissance of cancer therapeutic antibodies. Drug Discov Today 2003; 8:503 - 10; http://dx.doi.org/10.1016/S1359-6446(03)02714-4; PMID: 12818520
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007; 39:271 - 8; http://dx.doi.org/10.1007/s12026-007-0073-4; PMID: 17917071
   PubMed Web of Science ®Google Scholar
• Chan HTC, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003; 63:5480 - 9; PMID: 14500384
   PubMed Web of Science ®Google Scholar
• Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119:2143 - 59; PMID: 19620786
   PubMed Web of Science ®Google Scholar
• Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012; 119:3523 - 33; http://dx.doi.org/10.1182/blood-2011-12-395541; PMID: 22354003
   PubMed Web of Science ®Google Scholar
• Lim SH, Beers SA, French RR, Johnson PWM, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95:135 - 43; http://dx.doi.org/10.3324/haematol.2008.001628; PMID: 19773256
   PubMed Web of Science ®Google Scholar
• Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood 2011; 117:2993 - 3001; http://dx.doi.org/10.1182/blood-2010-07-298356; PMID: 21209380
   PubMed Web of Science ®Google Scholar
• Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 2010; 28:3035 - 41; http://dx.doi.org/10.1200/JCO.2009.27.8325; PMID: 20458031
   PubMed Web of Science ®Google Scholar
• Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393 - 402; http://dx.doi.org/10.1182/blood-2009-06-225979; PMID: 20194898
   PubMed Web of Science ®Google Scholar
• Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012; 119:5126 - 32; http://dx.doi.org/10.1182/blood-2012-01-404368; PMID: 22431570
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Forero-Torres A, LoBuglio AF. TRAIL-receptor antibodies as a potential cancer treatment. Future Oncol 2007; 3:405 - 9; http://dx.doi.org/10.2217/14796694.3.4.405; PMID: 17661715
   PubMedGoogle Scholar
• Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, et al. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011; 19:101 - 13; http://dx.doi.org/10.1016/j.ccr.2010.11.012; PMID: 21251615
   PubMed Web of Science ®Google Scholar
• Trarbach T, Moehler M, Heinemann V, Köhne CH, Przyborek M, Schulz C, et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010; 102:506 - 12; http://dx.doi.org/10.1038/sj.bjc.6605507; PMID: 20068564
   PubMed Web of Science ®Google Scholar
• Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13:6187 - 94; http://dx.doi.org/10.1158/1078-0432.CCR-07-0950; PMID: 17947486
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010; 21:376 - 81; http://dx.doi.org/10.1093/annonc/mdp292; PMID: 19633048
   PubMed Web of Science ®Google Scholar
• Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010; 16:1256 - 63; http://dx.doi.org/10.1158/1078-0432.CCR-09-1267; PMID: 20145186
   PubMed Web of Science ®Google Scholar
• Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 2010; 16:5883 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-10-0631; PMID: 20947515
   PubMed Web of Science ®Google Scholar
• Huet H, Schuller A, Li J, Johnson J, Dombrecht B, Meerschaert K, et al. TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012; 72(8 Suppl):Abstract nr 3853. doi:1538-7445.AM2012-3853.
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335 - 42; http://dx.doi.org/10.1056/NEJMoa032691; PMID: 15175435
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145 - 7; http://dx.doi.org/10.1038/nm988; PMID: 14745444
   PubMed Web of Science ®Google Scholar
• Marcucci F, Corti A. How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs. Adv Drug Deliv Rev 2012; 64:53 - 68; http://dx.doi.org/10.1016/j.addr.2011.09.007; PMID: 21983328
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427 - 34; http://dx.doi.org/10.1056/NEJMoa021491; PMID: 12890841
   PubMed Web of Science ®Google Scholar
• Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131:463 - 75; http://dx.doi.org/10.1016/j.cell.2007.08.038; PMID: 17981115
   PubMed Web of Science ®Google Scholar
• Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27:3557 - 65; http://dx.doi.org/10.1200/JCO.2008.19.6683; PMID: 19546406
   PubMed Web of Science ®Google Scholar
• Huang H, Lai J-Y, Do J, Liu D, Li L, Del Rosario J, et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 2011; 17:1001 - 11; http://dx.doi.org/10.1158/1078-0432.CCR-10-2317; PMID: 21233403
   PubMed Web of Science ®Google Scholar
• Rosen PJ, Sweeney CJ, Park DJ, Beaupre DM, Deng H, Leitch IM, et al. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010; 16:2677 - 87; http://dx.doi.org/10.1158/1078-0432.CCR-09-2862; PMID: 20406832
   PubMed Web of Science ®Google Scholar
• Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 2011; 17:611 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-10-1731; PMID: 21127194
   PubMed Web of Science ®Google Scholar
• Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, et al. HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 2012; 72:230 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-11-2001; PMID: 22102692
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39 - 51; http://dx.doi.org/10.1056/NEJMra043186; PMID: 17611206
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757 - 65; http://dx.doi.org/10.1056/NEJMoa0804385; PMID: 18946061
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626 - 34; http://dx.doi.org/10.1200/JCO.2007.14.7116; PMID: 18316791
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. J Clin Oncol 2010; 28:4769 - 77; http://dx.doi.org/10.1200/JCO.2009.27.4365; PMID: 20921461
   PubMed Web of Science ®Google Scholar
• Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007; 67:11991 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-07-2068; PMID: 18089830
   PubMed Web of Science ®Google Scholar
• Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27:1122 - 9; http://dx.doi.org/10.1200/JCO.2008.18.0463; PMID: 19164213
   PubMed Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23:7024 - 31; http://dx.doi.org/10.1200/JCO.2005.01.9950; PMID: 16145065
   PubMed Web of Science ®Google Scholar
• Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004; 89:1476 - 83; PMID: 15590398
   PubMed Web of Science ®Google Scholar
• Zent CS, Secreto CR, LaPlant BR, Bone ND, Call TG, Shanafelt TD, et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008; 32:1849 - 56; http://dx.doi.org/10.1016/j.leukres.2008.05.014; PMID: 18584865
   PubMed Web of Science ®Google Scholar
• Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 2010; 28:3525 - 30; http://dx.doi.org/10.1200/JCO.2010.27.9836; PMID: 20458041
   PubMed Web of Science ®Google Scholar
• Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010; 16:4331 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-10-0570; PMID: 20601446
   PubMed Web of Science ®Google Scholar
• Tawara T, Hasegawa K, Sugiura Y, Harada K, Miura T, Hayashi S, et al. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol 2008; 180:2294 - 8; PMID: 18250438
   PubMed Web of Science ®Google Scholar
• van der Kolk LE, Grillo-López AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115:807 - 11; http://dx.doi.org/10.1046/j.1365-2141.2001.03166.x; PMID: 11843813
   PubMed Web of Science ®Google Scholar
• Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008; 111:1456 - 63; http://dx.doi.org/10.1182/blood-2007-02-074716; PMID: 18024795
   PubMed Web of Science ®Google Scholar
• Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the complement cascade. Mol Cancer Res 2010; 8:1453 - 65; http://dx.doi.org/10.1158/1541-7786.MCR-10-0225; PMID: 20870736
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517 - 26; http://dx.doi.org/10.1056/NEJMoa1104621; PMID: 21639810
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 2010; 16:3485 - 94; http://dx.doi.org/10.1158/1078-0432.CCR-10-0505; PMID: 20479064
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167 - 75; http://dx.doi.org/10.1200/JCO.2009.26.7609; PMID: 20516446
   PubMed Web of Science ®Google Scholar
• Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood 2009; 113:3809 - 12; http://dx.doi.org/10.1182/blood-2008-10-185280; PMID: 19196657
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr., Corso SW, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol 2002; 20:4261 - 7; http://dx.doi.org/10.1200/JCO.2002.08.674; PMID: 12377971
   PubMed Web of Science ®Google Scholar
• Abès R, Gélizé E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116:926 - 34; http://dx.doi.org/10.1182/blood-2009-10-248609; PMID: 20439625
   PubMed Web of Science ®Google Scholar
• Selenko N, Maidic O, Draxier S, Berer A, Jäger U, Knapp W, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001; 15:1619 - 26; http://dx.doi.org/10.1038/sj.leu.2402226; PMID: 11587221
   PubMed Web of Science ®Google Scholar
• Park SG, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160 - 70; http://dx.doi.org/10.1016/j.ccr.2010.06.014; PMID: 20708157
   PubMed Web of Science ®Google Scholar
• zum Büschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 2002; 62:2244 - 7; PMID: 11956077
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 2006; 94:259 - 67; http://dx.doi.org/10.1038/sj.bjc.6602930; PMID: 16404427
   PubMed Web of Science ®Google Scholar
• Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007; 13:5133 - 43; http://dx.doi.org/10.1158/1078-0432.CCR-07-0507; PMID: 17785568
   PubMed Web of Science ®Google Scholar
• Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, et al. Suppression of Ewing’s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 2007; 13:4867 - 73; http://dx.doi.org/10.1158/1078-0432.CCR-07-0133; PMID: 17699866
   PubMed Web of Science ®Google Scholar
• Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116:1955 - 62; http://dx.doi.org/10.1172/JCI26532; PMID: 16794736
   PubMed Web of Science ®Google Scholar
• Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009; 8:2861 - 71; http://dx.doi.org/10.1158/1535-7163.MCT-09-0195; PMID: 19825804
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974 - 7; http://dx.doi.org/10.1126/science.1158545; PMID: 18703743
   PubMed Web of Science ®Google Scholar
• O’Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, et al. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 2001; 19:2413 - 21; PMID: 11331320
   PubMed Web of Science ®Google Scholar
• Ning S, Tian J, Marshall DJ, Knox SJ. Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res 2010; 70:7591 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-10-1639; PMID: 20841470
   PubMed Web of Science ®Google Scholar
• Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008; 60:1421 - 34; http://dx.doi.org/10.1016/j.addr.2008.04.012; PMID: 18541331
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436 - 44; http://dx.doi.org/10.1038/nature07205; PMID: 18650914
   PubMed Web of Science ®Google Scholar
• Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76:301 - 14; http://dx.doi.org/10.1016/0092-8674(94)90337-9; PMID: 7507411
   PubMed Web of Science ®Google Scholar
• Piali L, Fichtel A, Terpe H-J, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995; 181:811 - 6; http://dx.doi.org/10.1084/jem.181.2.811; PMID: 7530765
   PubMed Web of Science ®Google Scholar
• Wu NZ, Klitzman B, Dodge R, Dewhirst MW. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res 1992; 52:4265 - 8; PMID: 1638539
   PubMed Web of Science ®Google Scholar
• Nooijen PTGA, Westphal JR, Eggermont AMM, Schalkwijk C, Max R, de Waal RMW, et al. Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am J Pathol 1998; 152:679 - 82; PMID: 9502409
   PubMed Web of Science ®Google Scholar
• Zhang H, Issekutz AC. Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668. Am J Pathol 2002; 160:2219 - 30; http://dx.doi.org/10.1016/S0002-9440(10)61169-8; PMID: 12057924
   PubMed Web of Science ®Google Scholar
• Pagès F, Galon J, Dieu-Nosjean M-C, Tartour E, Sautès-Fridman C, Fridman W-H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29:1093 - 102; http://dx.doi.org/10.1038/onc.2009.416; PMID: 19946335
   PubMed Web of Science ®Google Scholar
• Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10:5650 - 5; http://dx.doi.org/10.1158/1078-0432.CCR-04-0225; PMID: 15355889
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754 - 8; http://dx.doi.org/10.1182/blood.V99.3.754; PMID: 11806974
   PubMed Web of Science ®Google Scholar
• Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940 - 7; http://dx.doi.org/10.1200/JCO.2003.05.013; PMID: 12975461
   PubMed Web of Science ®Google Scholar
• Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström’s macroglobulinemia. J Clin Oncol 2005; 23:474 - 81; http://dx.doi.org/10.1200/JCO.2005.06.059; PMID: 15659493
   PubMed Web of Science ®Google Scholar
• Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789 - 96; http://dx.doi.org/10.1200/JCO.2007.14.8957; PMID: 18347005
   PubMed Web of Science ®Google Scholar
• Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H, et al. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res 2011; 17:5668 - 73; http://dx.doi.org/10.1158/1078-0432.CCR-11-0239; PMID: 21788356
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563 - 72; http://dx.doi.org/10.1056/NEJMoa0808268; PMID: 19196673
   PubMed Web of Science ®Google Scholar
• Bonertz A, Weitz J, Pietsch D-HK, Rahbari NN, Schlude C, Ge Y, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009; 119:3311 - 21; PMID: 19809157
   PubMed Web of Science ®Google Scholar
• Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int 2011; 107:1500 - 6; http://dx.doi.org/10.1111/j.1464-410X.2010.09555.x; PMID: 20735382
   PubMed Web of Science ®Google Scholar
• Netti PA, Hamberg LM, Babich JW, Kierstead D, Graham W, Hunter GJ, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A 1999; 96:3137 - 42; http://dx.doi.org/10.1073/pnas.96.6.3137; PMID: 10077650
   PubMed Web of Science ®Google Scholar
• Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 2006; 66:1434 - 45; http://dx.doi.org/10.1158/0008-5472.CAN-05-0923; PMID: 16452199
   PubMed Web of Science ®Google Scholar
• Khawli LA, Hu P, Epstein AL. NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res 2005; 11:3084 - 93; http://dx.doi.org/10.1158/1078-0432.CCR-04-2310; PMID: 15837764
   PubMed Web of Science ®Google Scholar
• Khawli LA, Miller GK, Epstein AL. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer 1994; 73:Suppl 824 - 31; http://dx.doi.org/10.1002/1097-0142(19940201)73:3+<824::AID-CNCR2820731312>3.0.CO;2-V; PMID: 8306266
   PubMedGoogle Scholar
• Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009; 16:510 - 20; http://dx.doi.org/10.1016/j.ccr.2009.10.013; PMID: 19962669
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010; 328:1031 - 5; http://dx.doi.org/10.1126/science.1183057; PMID: 20378772
   PubMed Web of Science ®Google Scholar
• Beyer I, van Rensburg R, Strauss R, Li ZY, Wang H, Persson J, et al. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res 2011; 71:7080 - 90; http://dx.doi.org/10.1158/0008-5472.CAN-11-2009; PMID: 21990319
   PubMed Web of Science ®Google Scholar
• Beyer I, Li Z, Persson J, Liu Y, van Rensburg R, Yumul R, et al. Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther 2011; 19:479 - 89; http://dx.doi.org/10.1038/mt.2010.256; PMID: 21081901
   PubMed Web of Science ®Google Scholar
• Choi IK, Lee YS, Yoo JY, Yoon AR, Kim H, Kim DS, et al. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther 2010; 17:190 - 201; http://dx.doi.org/10.1038/gt.2009.142; PMID: 19907500
   PubMed Web of Science ®Google Scholar
• Pietras K, Östman A, Sjöquist M, Buchdunger E, Reed RK, Heldin C-H, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61:2929 - 34; PMID: 11306470
   PubMed Web of Science ®Google Scholar
• Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin C-H, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62:5476 - 84; PMID: 12359756
   PubMed Web of Science ®Google Scholar
• Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin C-H, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003; 9:3779 - 87; PMID: 14506171
   PubMed Web of Science ®Google Scholar
• Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kurizaki T, Nearman J, et al. Effect of platelet-derived growth factor receptor-β inhibition with STI571 on radioimmunotherapy. Cancer Res 2005; 65:7824 - 31; PMID: 16140951
   PubMed Web of Science ®Google Scholar
• Eikenes L, Bruland OS, Brekken C, Davies CdeL. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res 2004; 64:4768 - 73; http://dx.doi.org/10.1158/0008-5472.CAN-03-1472; PMID: 15256445
   PubMed Web of Science ®Google Scholar
• Brekken C, Hjelstuen MH, Bruland OS, de Lange Davies C. Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer Res 2000; 20:5B 3513 - 9; PMID: 11131655
   PubMed Web of Science ®Google Scholar
• Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE 3rd. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res 2006; 66:517 - 26; http://dx.doi.org/10.1158/0008-5472.CAN-05-2429; PMID: 16397268
   PubMed Web of Science ®Google Scholar
• Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, et al. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 2003; 9:2440 - 6; PMID: 12855616
   PubMed Web of Science ®Google Scholar
• Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE 3rd, Caligiuri M, et al. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res 2002; 8:3718 - 27; PMID: 12473581
   PubMed Web of Science ®Google Scholar
• Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004; 10:2253 - 64; http://dx.doi.org/10.1158/1078-0432.CCR-1087-3; PMID: 15073100
   PubMed Web of Science ®Google Scholar
• Cheung IY, Hsu K, Cheung N-KV. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2012; 30:426 - 32; http://dx.doi.org/10.1200/JCO.2011.37.6236; PMID: 22203761
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al, Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324 - 34; http://dx.doi.org/10.1056/NEJMoa0911123; PMID: 20879881
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005; 11:5984 - 92; http://dx.doi.org/10.1158/1078-0432.CCR-05-0577; PMID: 16115943
   PubMed Web of Science ®Google Scholar
• Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004; 5:141 - 9; http://dx.doi.org/10.1038/ni1029; PMID: 14704792
   PubMed Web of Science ®Google Scholar
• Moschetta M, Pretto F, Berndt A, Galler K, Richter P, Bassi A, et al. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res 2012; 72:1814 - 24; http://dx.doi.org/10.1158/0008-5472.CAN-11-1919; PMID: 22392081
   PubMed Web of Science ®Google Scholar
• Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000; 18:1185 - 90; http://dx.doi.org/10.1038/81183; PMID: 11062439
   PubMed Web of Science ®Google Scholar
• Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002; 110:475 - 82; PMID: 12189241
   PubMed Web of Science ®Google Scholar
• Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, et al. Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 2012; 188:2687 - 94; http://dx.doi.org/10.4049/jimmunol.1101877; PMID: 22323546
   PubMed Web of Science ®Google Scholar
• Bellone M, Calcinotto A, Corti A. Won’t you come on in? How to favor lymphocyte infiltration in tumors. OncoImmunology 2012; 1:98 - 9; http://dx.doi.org/10.4161/onci.20213
   Google Scholar
• Johansson A, Hamzah J, Payne CJ, Ganss R. Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A 2012; 109:7841 - 6; http://dx.doi.org/10.1073/pnas.1118296109; PMID: 22547817
   PubMed Web of Science ®Google Scholar
• Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12:235 - 9; http://dx.doi.org/10.1038/nm1351; PMID: 16462802
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010; 70:5270 - 80; http://dx.doi.org/10.1158/0008-5472.CAN-10-0012; PMID: 20530679
   PubMed Web of Science ®Google Scholar
• Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171 - 80; http://dx.doi.org/10.1158/0008-5472.CAN-10-0153; PMID: 20631075
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58 - 62; http://dx.doi.org/10.1126/science.1104819; PMID: 15637262
   PubMed Web of Science ®Google Scholar
• Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011; 6:e19499; http://dx.doi.org/10.1371/journal.pone.0019499; PMID: 21559358
   PubMed Web of Science ®Google Scholar
• Fisher DT, Chen Q, Skitzki JJ, Muhitch JB, Zhou L, Appenheimer MM, et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest 2011; 121:3846 - 59; http://dx.doi.org/10.1172/JCI44952; PMID: 21926464
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466 - 73; http://dx.doi.org/10.1074/jbc.M210665200; PMID: 12427744
   PubMed Web of Science ®Google Scholar
• Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004; 87:614 - 22; http://dx.doi.org/10.1002/bit.20151; PMID: 15352059
   PubMed Web of Science ®Google Scholar
• Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 2004; 336:1239 - 49; http://dx.doi.org/10.1016/j.jmb.2004.01.007; PMID: 15037082
   PubMed Web of Science ®Google Scholar
• Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 2010; 70:4481 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-09-3704; PMID: 20484044
   PubMed Web of Science ®Google Scholar
• Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30:837 - 42; http://dx.doi.org/10.1200/JCO.2011.37.3472; PMID: 22312108
   PubMed Web of Science ®Google Scholar
• Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17:176 - 80; http://dx.doi.org/10.1038/6179; PMID: 10052355
   PubMed Web of Science ®Google Scholar
• Hamilton SR, Davidson RC, Sethuraman N, Nett JH, Jiang Y, Rios S, et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 2006; 313:1441 - 3; http://dx.doi.org/10.1126/science.1130256; PMID: 16960007
   PubMed Web of Science ®Google Scholar
• Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 2006; 24:210 - 5; http://dx.doi.org/10.1038/nbt1178; PMID: 16429149
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005 - 10; http://dx.doi.org/10.1073/pnas.0508123103; PMID: 16537476
   PubMed Web of Science ®Google Scholar
• Desjarlais JR, Lazar GA. Modulation of antibody effector function. Exp Cell Res 2011; 317:1278 - 85; http://dx.doi.org/10.1016/j.yexcr.2011.03.018; PMID: 21459085
   PubMed Web of Science ®Google Scholar
• Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 2012; 11:311 - 31; http://dx.doi.org/10.1038/nrd2909; PMID: 22460124
   PubMed Web of Science ®Google Scholar
• Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99:1441 - 54; http://dx.doi.org/10.1093/jnci/djm135; PMID: 17895480
   PubMed Web of Science ®Google Scholar
• Marcucci F, Corti A. Improving drug penetration to curb tumor drug resistance. Drug Discov Today 2012; 17:1139 - 46; http://dx.doi.org/10.1016/j.drudis.2012.06.004; PMID: 22706017
   PubMed Web of Science ®Google Scholar